GTCR to Acquire Surmodics for $43.00 per Share; Equity Value Approximately $627M

Surmodics Acquires Vetex Medical Limited

July 6, 2021

Medical Devices

Surmodics, Inc. (NASDAQ: SRDX) acquired Galway-based Vetex Medical Limited to expand its thrombectomy portfolio with the ReVene Thrombectomy Catheter. The deal included an upfront payment of $39.9 million and up to $7 million in additional milestone payments (with $3.5 million guaranteed), giving Surmodics a second FDA 510(k)-cleared mechanical thrombectomy device and IP to accelerate its thrombectomy platform development.

GTCR Announces $200M Strategic Minority Investment in Solmetex

October 15, 2025

Dental

GTCR has made a structured minority investment of up to $200 million in Solmetex to fund the company's growth initiatives and support near-term add-on acquisitions. GTCR will partner with existing shareholders including AGIC Capital and Solmetex CEO Gene Dorff to scale the company's dental products and consumables business serving more than 85,000 U.S. dental practices.

Surmodics Merges with Biocoat; Forms Surmodics Services & Technologies Division

December 10, 2025

Medical Devices

Surmodics has completed a merger with Biocoat and formed a new division, Surmodics Services & Technologies (SST), to carry forward the portion of Biocoat's business remaining after divesting certain assets. SST, based in Horsham, Pennsylvania, will provide hydrophilic coating technologies, custom polymer formulations and full-service coating operations to medical device manufacturers worldwide.

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.

GTCR Invests $1.33 Billion in Tricentis

November 26, 2024

Software

GTCR has signed a definitive agreement to invest $1.33 billion in Tricentis, valuing the enterprise at $4.5 billion. Insight Partners will continue as a significant investor and will work with GTCR with equal board representation as Tricentis uses the capital to fuel growth, product innovation, and global expansion.

Syncona to Acquire Applied Genetic Technologies Corporation

October 23, 2022

Biotechnology

Syncona Limited will acquire Applied Genetic Technologies Corporation (AGTC) via a tender offer, paying $0.34 per share in cash upfront (approximately $23.5 million) with contingent value rights (CVRs) that could provide up to an additional $0.73 per share (up to $50.0 million) for total potential consideration of up to $1.07 per share. The transaction, unanimously approved by AGTC’s board, will take AGTC private and is intended to advance AGTC's retinal gene therapy programs amid funding challenges for the public company.